Aegerion Pharmaceuticals Inc. (AEGR) Now Covered by JPMorgan Chase & Co.
Research analysts at JPMorgan Chase & Co. began coverage on shares of Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) in a report issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Separately, Zacks Investment Research raised Aegerion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $10.50.
Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) opened at 1.82 on Friday. The stock’s market cap is $53.77 million. The firm has a 50 day moving average price of $2.19 and a 200 day moving average price of $1.84. Aegerion Pharmaceuticals has a 12-month low of $1.23 and a 12-month high of $10.85.
In related news, major shareholder Healthcare Master Fun Broadfin purchased 276,000 shares of the business’s stock in a transaction on Monday, September 12th. The stock was acquired at an average price of $1.66 per share, with a total value of $458,160.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.60% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Ancora Advisors LLC bought a new stake in Aegerion Pharmaceuticals during the second quarter valued at about $114,000. Eqis Capital Management Inc. raised its stake in Aegerion Pharmaceuticals by 3.9% in the second quarter. Eqis Capital Management Inc. now owns 87,458 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 3,255 shares in the last quarter. Paloma Partners Management Co bought a new stake in Aegerion Pharmaceuticals during the second quarter valued at about $142,000. FNY Managed Accounts LLC raised its stake in Aegerion Pharmaceuticals by 142.0% in the third quarter. FNY Managed Accounts LLC now owns 49,372 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 28,972 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Aegerion Pharmaceuticals during the first quarter valued at about $574,000. 87.16% of the stock is owned by institutional investors and hedge funds.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Stock Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.